Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>BeOne Medicines recently announced its financial results for the second quarter of fiscal year 2025.</li><li>The company reported significant financial and strategic progress, reinforcing its position in the market.</li><li>Breaking down the results, BeOne's revenue reached $1.3 billion, reflecting a robust 42% year-over-year growth.</li></ul>

BeOne Medicines recently announced its financial results for the second quarter of fiscal year 2025.The company reported significant financial and strategic progress, reinforcing its position in the market.Breaking down the results, BeOne's revenue reached $1.3 billion, reflecting a robust 42% year-over-year growth.

BeOne Medicines: Initiation of Coverage- 20 expected R&D milestones In The Next 18 Months Signalling A Massive Upside? – Major Drivers

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>BeiGene’s 25Q2 performance beat expectations. The main driver was still BRUKINSA. The growth rate of tislelizumab was surprising.Sales of tislelizumab in international market is expected to be reflected in 25H2.</li>
<li>BeiGene's turnaround from losses to profits has entered the countdown.However, investors may not be happy with the net profit margin brought by single revenue driver Brukinsa based on our calculation.</li>
<li>There’s no next blockbuster that can drive BeiGene to a big step forward.This is why the market is reluctant to offer higher valuation, despite current high growth in product revenue.</li>
</ul>


BeiGene’s 25Q2 performance beat expectations. The main driver was still BRUKINSA. The growth rate of tislelizumab was surprising.Sales of tislelizumab in international market is expected to be reflected in 25H2.
BeiGene's turnaround from losses to profits has entered the countdown.However, investors may not be happy with the net profit margin brought by single revenue driver Brukinsa based on our calculation.
There’s no next blockbuster that can drive BeiGene to a big step forward.This is why the market is reluctant to offer higher valuation, despite current high growth in product revenue.


BeiGene (6160.HK/​ONC US) 25Q2 - The High Growth of BRUKINSA May Not Bring High Valuation

<ul>
<li>Trump threatened to levy tariffs on pharmaceuticals, but the BD model of Chinese innovative drugs will be less affected, because the essence is licensing-out model, not physical drug exports.</li>
<li>The long-awaited national VBP of biosimilar drugs has moved from policy incubation period to substantive operation stage, which is expected to change the market structure after big price reduction.</li>
<li>BeiGene’s 25Q2 results beat expectations. Reasonable market value is about US$40-42.4 billion. However, the market is reluctant to offer higher valuation due to the concerns on the outlook of BeiGene. </li>
</ul>


Trump threatened to levy tariffs on pharmaceuticals, but the BD model of Chinese innovative drugs will be less affected, because the essence is licensing-out model, not physical drug exports.
The long-awaited national VBP of biosimilar drugs has moved from policy incubation period to substantive operation stage, which is expected to change the market structure after big price reduction.
BeiGene’s 25Q2 results beat expectations. Reasonable market value is about US$40-42.4 billion. However, the market is reluctant to offer higher valuation due to the concerns on the outlook of BeiGene. 


China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene (6160 HK)</a> reported 2Q25 revenues of $1.3B, up 42% YoY (1H25 Revenue: $2.4B, up 45%), driven primarily by growth in Brukinsa sales in the U.S. and Europe.</li>
<li>In 2Q25, U.S. sale of Brukinsa was $684M, up 43% YoY. For three consecutive quarters now, Brukinsa outpaced its closest competitor Calquence which reported US revenue of $583M in 2Q25.</li>
<li>BeiGene now expects 2025 revenue to be in the range of $5.0–5.3B (up 29–39% YoY) compared to the previous revenue guidance of $4.9–5.3B.</li>
</ul>



BeiGene (6160 HK) reported 2Q25 revenues of $1.3B, up 42% YoY (1H25 Revenue: $2.4B, up 45%), driven primarily by growth in Brukinsa sales in the U.S. and Europe.
In 2Q25, U.S. sale of Brukinsa was $684M, up 43% YoY. For three consecutive quarters now, Brukinsa outpaced its closest competitor Calquence which reported US revenue of $583M in 2Q25.
BeiGene now expects 2025 revenue to be in the range of $5.0–5.3B (up 29–39% YoY) compared to the previous revenue guidance of $4.9–5.3B.


BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

<ul><li>Sales of zanubrutinib remained strong. For 1H25, BeOne reported total revenue of US$2.43bn (+45% YoY), achieving 46% of our previous full-year forecast, in line with our expectations.</li><li>In 2Q25, zanubrutinib (Zanu) sales reached US$950mn, +49% YoY and +20% QoQ, significantly outperforming ibrutinib (+3% QoQ) and acalabrutinib (+14% QoQ).</li><li>In the US, Zanu remains the top BTKi by revenue since 1Q25 and leads in new patient prescriptions across both 1L and RR CLL treatment settings. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sales of zanubrutinib remained strong. For 1H25, BeOne reported total revenue of US$2.43bn (+45% YoY), achieving 46% of our previous full-year forecast, in line with our expectations.In 2Q25, zanubrutinib (Zanu) sales reached US$950mn, +49% YoY and +20% QoQ, significantly outperforming ibrutinib (+3% QoQ) and acalabrutinib (+14% QoQ).In the US, Zanu remains the top BTKi by revenue since 1Q25 and leads in new patient prescriptions across both 1L and RR CLL treatment settings. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeOne Medicines (ONC US) - Solid 2Q Results, Eyes on CDK4i Readouts by Year-End

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (6160 HK)

BeOne Medicines: Initiation of Coverage- 20 expected R&D milestones In The Next 18 Months Signalling A Massive Upside? – Major Drivers

BeOne Medicines recently announced its financial results for the second quarter of fiscal year 2025. The company reported significant financial...

Baptista Research

BeiGene (6160.HK/ONC US) 25Q2 - The High Growth of BRUKINSA May Not Bring High Valuation

BeiGene's strong Q2 growth driven by BRUKINSA, but concerns remain about overreliance on single revenue driver/lack of next blockbuster for future...

Xinyao (Criss) Wang

China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2

Trump's threat of tariffs on drugs won't impact China innovative drug BD deals. Biosimilar VBP is expected to reshape market. BeiGene released...

Xinyao (Criss) Wang

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

BeiGene reported strong 2Q25 revenues of $1.3B, driven by Brukinsa sales in US and Europe. U.S. Brukinsa sales outpaced competitor for three...

Tina Banerjee

BeOne Medicines (ONC US) - Solid 2Q Results, Eyes on CDK4i Readouts by Year-End

Sales of zanubrutinib remained strong. For 1H25, BeOne reported total revenue of US$2.43bn (+45% YoY), achieving 46% of our previous full-year...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BeOne Medicines: Initiation of Coverage- 20 expected R&D milestones In The Next 18 Months Signalling A Massive Upside? – Major Drivers

BeOne Medicines recently announced its financial results for the second quarter of fiscal year 2025. The company reported significant financial...

Baptista Research

BeiGene (6160.HK/​ONC US) 25Q2 - The High Growth of BRUKINSA May Not Bring High Valuation

​BeiGene's strong Q2 growth driven by BRUKINSA, but concerns remain about overreliance on single revenue driver/lack of next blockbuster for future...

Xinyao (Criss) Wang

China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2

​Trump's threat of tariffs on drugs won't impact China innovative drug BD deals. Biosimilar VBP is expected to reshape market. BeiGene released...

Xinyao (Criss) Wang

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

​BeiGene reported strong 2Q25 revenues of $1.3B, driven by Brukinsa sales in US and Europe. U.S. Brukinsa sales outpaced competitor for three...

Tina Banerjee

BeOne Medicines (ONC US) - Solid 2Q Results, Eyes on CDK4i Readouts by Year-End

Sales of zanubrutinib remained strong. For 1H25, BeOne reported total revenue of US$2.43bn (+45% YoY), achieving 46% of our previous full-year...

CMB International

BeiGene (6160.HK/ONC US) 25Q2 - The High Growth of BRUKINSA May Not Bring High Valuation

BeiGene's strong Q2 growth driven by BRUKINSA, but concerns remain about overreliance on single revenue driver/lack of next blockbuster for future...

Trump's threat of tariffs on drugs won't impact China innovative drug BD deals. Biosimilar VBP is expected to reshape market. BeiGene released...

BeiGene reported strong 2Q25 revenues of $1.3B, driven by Brukinsa sales in US and Europe. U.S. Brukinsa sales outpaced competitor for three...